The IS-free rates for PCa patients exposed to GnRH agonist, antiandrogens, and those who were ADT-naïve were 94.8%, 94.7%, and 95.5%, respectively, while the CVD-free rates were 92.9%, 93.3%, and 94.6%, respectively (Figure 3). The gene discussed is GNRH1; the disease is posterior cortical atrophy.